![]() ![]() Thus, technically, is it possible to produce an oral solid dosage form containing a drug with limited stability, poor compressibility, or inappropriate organoleptic properties. In 2001, capsules accounted for approximately 20% of all prescriptions dispensed. By 1996, the percentage had already reached 34%. In 1982, only 17.5% of newly licensed products were presented as hard gelatin capsules. ![]() Since ECDDT is a new technology, this article is based on a limited number of references. This literature review presents their composition and properties. Although not all capsules in all formulations meet pharmaceutical requirements for delayed-release dosage forms in disintegration and dissolution tests, they usually find practical application. These include DRcaps ®, EMBO CAPS ® AP, BioVXR ®, or ACGcaps™ HD. Manufacturers supply these types of capsules, made from pH-soluble polymers, in products such as AR Caps ®, EnTRinsic TM, and Vcaps ® Enteric, or capsules made of gelling polymers that release their content as the gel erodes over time when passing through the digestive tract. A suitable method seems to be the encapsulation of drugs or lyophilized alternatively frozen biological suspensions in commercial hard enteric capsules prepared by so-called Enteric Capsule Drug Delivery Technology (ECDDT). Currently, there is a growing need to prepare small batches of enteric capsules for individual therapy or clinical evaluation since many acidic-sensitive substances should be protected from the stomach’s acidic environment, including probiotics or fecal material, in the fecal microbiota transplantation (FMT) process.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |